Psychiatry Investig.
2018 Jun;15(6):628-637. 10.30773/pi.2018.01.18.1.
Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
- Affiliations
-
- 1Department of Psychiatry, Eulji University School of Medicine, Eulji University Hospital, Daejeon, Republic of Korea.
- 2Department of Neuropsychiatry and Institute of Clinical Psychopharmacology, Dongguk University International Hospital, Goyang, Republic of Korea. kys@snu.ac.kr
- 3Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.
- 4Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul, Republic of Korea.
- 5College of Nursing Science, Ewha Woman’s University, Seoul, Republic of Korea.
- KMID: 2428888
- DOI: http://doi.org/10.30773/pi.2018.01.18.1
Abstract
OBJECTIVE
Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Despite the risk of MetS, SGAs may have to be continued with change in some patients. The aim of this study was to trace the evolution of MetS in these patients.
METHODS
Patients with schizophrenia who had been maintained on a fixed SGA regimen for more than a year were followed-up without changing the regimen. Metabolic indicators were evaluated at baseline and at follow-up. Prevalence, incidence and spontaneous normalization rate of MetS were estimated. Risk factors that might have influenced the evolution were scrutinized.
RESULTS
A total of 151 subjects were included. During the mean observation period of 389.9±162.4 days, the prevalence of MetS was increased from 35.1 to 45.0%. The incidence rate was 29.6%, while the normalization rate was 26.4%, risk factors affecting incidence were age (OR=1.09, 95% CI: 1.03-1.17), baseline continuous values of metabolic syndrome risk scores (cMetS, OR=1.77, 95% CI:1.29-2.55) and baseline body weight (OR=1.06, 95% CI: 1.01-1.13). Normalization was influenced by age (OR=0.74, 95% CI: 0.57-0.89) and baseline body weight (OR=0.85, 95% CI: 0.72-0.95).
CONCLUSION
The prevalence of MetS steadily increased with the continuous use of SGAs. However, individual difference was extensive and about a quarter of the patients were able to recover naturally without specific measurements.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Metabolic Side Effects of Antipsychotic Medication: An Overview
- Long-acting Injectable Antipsychotics in First-episode Schizophrenia
- Breakthrough Psychosis and Long-Acting Injectable Antipsychotics
- Current advances in pharmacotherapy for schizophrenia
- Recent Trends of Antipsychotics Polypharmacy in Schizophrenia
